



## Radiation Therapy in Lung Cancer: From a Technical Revolution to a Combination with New Systemic Approaches

Guest Editors:

**Dr. Alessio Bruni**

Radiation Therapy Unit,  
University Hospital of Modena,  
Modena, Italy

**Dr. Paolo Borghetti**

Radiation Therapy Unit, "Spedali  
Civili" University Hospital of  
Brescia, Brescia, Italy

Deadline for manuscript  
submissions:

**closed (15 June 2023)**

### Message from the Guest Editors

There has been a recent, significant improvement in the field of radiation therapy due to the introduction and worldwide use of new highly sophisticated techniques, such as IGRT, VMAT, and SBRT. Additionally, new systemic therapies are currently available, including immunotherapy, which may be used in combination with radiation therapy, achieving intriguing results in relation to the subject of survival without increasing toxicities. For this reason, new studies are invited for submission, to increase the body of the literature available on this topic and to share the experiences that may aid clinicians in their clinical practice.

We are pleased to invite valuable and important submissions to this journal, with the aim that the conducted research will contribute to the scientific knowledge, local or systemic therapeutic options, to optimize the multidisciplinary management of lung cancer:

- Non-small cell lung cancer;
- Small-cell lung cancer;
- Neoadjuvant/adjuvant treatment in resectable NSCLC;
- Stereotactic body radiotherapy for early stage NSCLC;
- Multidisciplinary management of advanced NSCLC and SCLC;
- Treatment of thymic cancer;
- Palliative RT.





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI